All In Biotech

Drug Trial Radar · NCT07321093

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

A Double-blind, Randomized Clinical Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

292

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.

Conditions

  • Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

  • BCD-281Biological

    anti-CD20 monoclonal antibody

  • OcrelizumabBiological

    anti-CD20 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of T1 gadolinium-enhancing (Gd+) lesions up to Week 24.Time frame: up to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • LLC "Medis"

    Nizhny Novgorod, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.